BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24621186)

  • 1. UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.
    Gregg K; Hakki M; Kaul DR
    Transpl Infect Dis; 2014 Apr; 16(2):320-3. PubMed ID: 24621186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
    Baldanti F; Lurain N; Gerna G
    Hum Immunol; 2004 May; 65(5):403-9. PubMed ID: 15172438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
    Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
    Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient.
    Miller GG; Boivin G; Dummer JS; McConnell T; Becher MW; Kassim A; Tang YW
    Clin Infect Dis; 2006 Feb; 42(4):e26-9. PubMed ID: 16421783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus drug resistance.
    Emery VC
    Antivir Ther; 1998; 3(4):239-42. PubMed ID: 10682146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
    Chou S; Miner RC; Drew WL
    J Infect Dis; 2000 Dec; 182(6):1765-8. PubMed ID: 11069251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
    Scott GM; Weinberg A; Rawlinson WD; Chou S
    Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanism of drug-resistance in human cytomegalovirus].
    Eizuru Y
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():476-9. PubMed ID: 17455666
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes.
    Eckle T; Prix L; Jahn G; Klingebiel T; Handgretinger R; Selle B; Hamprecht K
    Blood; 2000 Nov; 96(9):3286-9. PubMed ID: 11050017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
    Drew WL; Miner RC; Marousek GI; Chou S
    J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation.
    Shapira MY; Resnick IB; Chou S; Neumann AU; Lurain NS; Stamminger T; Caplan O; Saleh N; Efferth T; Marschall M; Wolf DG
    Clin Infect Dis; 2008 May; 46(9):1455-7. PubMed ID: 18419454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
    Goldsmith PM; Husain MM; Carmichael A; Zhang H; Middleton SJ
    Transplantation; 2012 Apr; 93(7):e30-2. PubMed ID: 22450598
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet.
    Hubacek P; Keslova P; Formankova R; Pochop P; Cinek O; Zajac M; Lochmanova J; Stary J; Sedlacek P
    Pediatr Transplant; 2009 Nov; 13(7):919-22. PubMed ID: 19067913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
    Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
    J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.
    Zaia JA
    Bone Marrow Transplant; 2002 Apr; 29(8):633-8. PubMed ID: 12180106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
    Boivin G; Goyette N; Gilbert C; Covington E
    J Med Virol; 2005 Nov; 77(3):425-9. PubMed ID: 16173018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.